Testing a new psoriasis shot for moderate to severe plaque
Part of Skin clinical trials.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have had plaque psoriasis for at least 6 months
- Your psoriasis is moderate to severe (covering at least 10% of your body)
- You are a candidate for systemic treatment (pills, injections) or light therapy
- You have not used certain biologic drugs recently (like Stelara or Cosentyx) or have never taken them
- You do not have other types of psoriasis (like pustular or guttate), active infections, or serious health conditions like inflammatory bowel disease or severe depression
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called SHR-1139 for people with moderate-to-severe plaque psoriasis. The goal is to see if it can safely improve your skin condition.
This trial tests an oral medication called HS-10374 for people with mild to moderate plaque psoriasis who haven't gotten enough relief from topical treatments. The study will check if the drug is safe and effective at clearing psoriasis patches.
This study tests an investigational oral medication called HS-10374 for moderate to severe plaque psoriasis. It aims to see how well it clears skin and prevents flares compared to a placebo, and if it is safe for long-term use.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This trial tests a new medication called HSK44459 for people with moderate to severe plaque psoriasis who need systemic therapy (medicine that works throughout the body). The goal is to see if it is safe and effective.
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.